Ballantyne CM - Search Results

1

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.

Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE. Nicholls SJ, et al. Among authors: ballantyne cm. Clin Cardiol. 2018 Oct;41(10):1281-1288. doi: 10.1002/clc.23055. Epub 2018 Sep 28. Clin Cardiol. 2018. PMID: 30125052 Free PMC article. Review.

2

Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin.

Herd JA, West MS, Ballantyne C, Farmer J, Gotto AM Jr. Herd JA, et al. Am J Cardiol. 1994 May 26;73(14):42D-49D. doi: 10.1016/0002-9149(94)90632-7. Am J Cardiol. 1994. PMID: 8198024 Clinical Trial.

3

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.

West MS, Herd JA, Ballantyne CM, Pownall HJ, Simpson S, Gould L, Gotto AM Jr. West MS, et al. Among authors: ballantyne cm. Control Clin Trials. 1996 Dec;17(6):550-83. doi: 10.1016/s0197-2456(96)00178-x. Control Clin Trials. 1996. PMID: 8974213 Clinical Trial.

4

Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]).

Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, Gould KL, Gotto AM Jr. Herd JA, et al. Among authors: ballantyne cm. Am J Cardiol. 1997 Aug 1;80(3):278-86. doi: 10.1016/s0002-9149(97)00346-9. Am J Cardiol. 1997. PMID: 9264419 Clinical Trial.

5

Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol.

Belalcazar LM, Ballantyne CM. Belalcazar LM, et al. Among authors: ballantyne cm. Prog Cardiovasc Dis. 1998 Sep-Oct;41(2):151-74. doi: 10.1016/s0033-0620(98)80010-8. Prog Cardiovasc Dis. 1998. PMID: 9790415 Review.

6

Low-density lipoproteins and risk for coronary artery disease.

Ballantyne CM. Ballantyne CM. Am J Cardiol. 1998 Nov 5;82(9A):3Q-12Q. doi: 10.1016/s0002-9149(98)00769-3. Am J Cardiol. 1998. PMID: 9819098 Review.

7

Reducing atherothrombotic events in high-risk patients: recent data on therapy with statins and fatty acids.

Ballantyne CM. Ballantyne CM. Curr Atheroscler Rep. 1999 Jul;1(1):6-8. doi: 10.1007/s11883-999-0043-5. Curr Atheroscler Rep. 1999. PMID: 11122685 Review.

8

Treating mixed dyslipidemias: why and how.

Ballantyne CM. Ballantyne CM. Clin Cardiol. 2001;24(7 Suppl):II-6-9. doi: 10.1002/clc.4960240704. Clin Cardiol. 2001. PMID: 11444652 Free PMC article. Review.

9

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels.

Ballantyne CM, Andrews TC, Hsia JA, Kramer JH, Shear C; ACCESS Study Group. Atorvastatin Comparative Cholesterol Efficacy and Safety Study. Ballantyne CM, et al. Am J Cardiol. 2001 Aug 1;88(3):265-9. doi: 10.1016/s0002-9149(01)01638-1. Am J Cardiol. 2001. PMID: 11472705 Clinical Trial.

10

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Ballantyne CM, et al. Circulation. 2001 Dec 18;104(25):3046-51. doi: 10.1161/hc5001.100624. Circulation. 2001. PMID: 11748098 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,024 results

Search Page